| dc.creator |
ÇETİN, Bülent |
|
| dc.creator |
Wabl, Chiara A. |
|
| dc.creator |
Gumusay, Ozge |
|
| dc.date |
2022-02-01T00:00:00Z |
|
| dc.date.accessioned |
2022-05-10T11:18:38Z |
|
| dc.date.available |
2022-05-10T11:18:38Z |
|
| dc.identifier |
63e3dab0-05d4-464a-87a0-c09c9e4774c1 |
|
| dc.identifier |
10.2217/fon-2021-0842 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/63e3dab0-05d4-464a-87a0-c09c9e4774c1/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/96671 |
|
| dc.description |
Hormone receptor (HR)-positive, HER2-negative tumors represent the most common form of metastatic breast cancer (MBC), and endocrine therapy has been the mainstay treatment for several decades. Recently, a novel drug class called CDK4/6 inhibitors in combination with endocrine therapy have remarkably improved the outcome of patients with HR-positive, HER2-negative MBC by targeting the cell cycle machinery and overcoming aspects of endocrine resistance. Several potential cell-cycle-specific and nonspecific mechanisms of resistance to CDK4/6 inhibitors have been reported in recent studies. This review discusses potential resistance mechanisms to CDK4/6 inhibitors, the use of biomarkers to guide treatment for HR-positive, HER2-negative MBC and possible approaches to overcome resistance to CDK4/6 inhibitors. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer |
|
| dc.type |
info:eu-repo/semantics/article |
|